| Parameters |
SC (14) |
SM (13) |
ARC (11) |
ARM (16) |
Disease |
Treatment |
D x T |
| Body Weight, g |
568 ± 9.9 |
580 ± 9.4 |
548 ± 5.3 |
552 ± 6.4 |
0.0047 |
0.34 |
0.69 |
| Tibial length, mm |
58 ± 0.5 |
58 ± 0.4 |
58 ± 0.4 |
58 ± 0.4 |
0.31 |
0.32 |
0.72 |
| Heart, mg |
1206 ± 42.0 |
1180 ± 30.7 |
1988 ± 58.2 |
1911 ± 31.4 |
<0.0001 |
0.22 |
0.54 |
| LV, mg |
875 ± 28.5 |
843 ± 19.4 |
1487 ± 55.4 |
1432 ± 26.9 |
<0.0001 |
0.22 |
0.75 |
| RV, mg |
231 ± 8.7 |
229 ± 7.0 |
340 ± 16.6 |
319 ± 7.9 |
<0.0001 |
0.28 |
0.36 |
SC: sham control (untreated), SM: sham metformin-treated animals, ARC, aortic regurgitation control group and ARM: aortic regurgitation metformin-treated animals. LV:
left ventricle and RV: right ventricle. Values are expressed as mean ± SEM. The number of animals per group is indicated in parenthesis. P values from 2-way ANOVA
analysis are shown on the right to evaluate separately the general impact of the disease or the metformin treatment and the interaction between disease and treatment (D
x T). |
